Menu
Meet the Program Commitee for 2023!
Program Committee
-
Venkatraman Balasubramanian, PhD, MBA • Healthcare and Life Sciences Strategic Advisor

VB Insights, LLC, United States -
Greg Ball, PhD • Safety Data Scientist

ASAPprocess, United States -
Amy Bertha • Executive Director, Regulatory Policy and Science

Bayer, United States -
Claire Blanchette, PMP • Executive Drug Development Program Leader

Daiichi Sankyo, United States -
Susan Callery-D'Amico, BSN • Retired, Vice President, R&D Quality Assurance, AbbVie

United States -
Brooke Casselberry, MS, RAC • Vice President, Advisory and Delivery

Epista Life Science, United States -
Meghana Chalasani, MHA • Associate Director for Clinical Trial Innovation, Office of New Drugs, CDER

FDA, United States -
Andrew Chang, PhD • Vice President, Quality and Regulatory Compliance

Novo Nordisk, United States -
Wendy Charles, PhD • Chief Ethics and Compliance Officer; Adjunct Faculty

Equideum Health, United States -
Ethan Chen, MBA, MS, PMP • Director, Division of Data Management

FDA CDER, United States -
Leah Christl, PhD • Exec Director, Global Biosimilars Regulatory Affairs & Regulatory & R&D Policy

Amgen, United States -
Mary Ellen Cosenza, PhD, MS, RAC • President

MEC Regulatory & Toxicology Consulting, LLC, United States -
Stephanie Y. Crawford, PhD, MPH, MS • Professor, Pharmacy Systems, Outcomes and Policy

University of Illinois at Chicago, United States -
Alysha Croker, PhD • Director, Strategic and Horizontal Policy

Health Canada, Canada -
Ebony Dashiell-Aje, PhD • Executive Director and Head, Patient Centered Outcomes Science

BioMarin, United States -
Julie Dietrich, MS • Senior Director, Clinical Development

United States -
Andrew Emmett, MPH • VP, Global Regulatory Policy and Global Intelligence

Pfizer Inc, United States -
Jennifer Farmer, MS • Chief Executive Officer

Friedreich's Ataxia Research Alliance (FARA), United States -
Maureen Feeney, PharmD, MBA, RPh • Vice President Scientific Communications and Strategic Alliances

Takeda, United States -
Ron Fitzmartin, PhD, MBA • Principal Consultant

Decision Analytics, United States -
David Fryrear, MS • Chief Quality Officer

Astellas, United States -
M. Scott Furness, PhD • Deputy Director, Office of New Drug Products, OPQ, CDER

FDA, United States -
Alicia Gilsenan, PhD, MS, RPh, FISPE • Vice President, Epidemiology

RTI Health Solutions, United States -
Cheryl Grandinetti, PharmD • Associate Director for Clinical Policy, CDER/OC/OSI/DCCE

FDA, United States -
Renmeet Grewal, PharmD, MS • Division Director, Office of Regulatory Operations (DRO-II), OND, CDER

FDA, United States -
Sabine Haubenreisser, PhD, MSc • Principal Scientific Administrator, Stakeholders and Communication Division

European Medicines Agency, Netherlands -
Alan Hochberg • Principal Scientific Enablement Director, Scientific Enablement and Processes

Genentech, A Member of the Roche Group, United States -
Michelle Hoiseth • General Manager, Project-Based Services

Cytel, United States -
Cammilla Horta Gomes, MA, MPharm • Latam Regulatory Policy Lead

Roche, Brazil -
Emily (Xianghong) Jing, PhD • Associate Director for Scientific Coordination, OBP, OPQ, CDER

FDA, United States -
Jeremy Jokinen, PhD, MS • Vice President and Head Global Patient Safety

Argenx, United States -
Cathryn C Lee, MSN •

United States -
Demetra Macheras, MBA • Director, Regulatory Policy and Intelligence - Regulatory Affairs

AbbVie, United States -
Nicole Mahoney, PhD • Executive Director US Regulatory Policy & Intelligence

Novartis, United States -
Sheila Mahoney Jewels, MBA • Drug Development Multi-Functionalist

LifeSciHub , United States -
Ingrid Markovic, PhD • Independent Expert

United States -
Lindsay McNair, MD, MPH, MS • Principal Consultant

Equipoise Consulting, United States -
Melodi J McNeil, MS, RPh • Director, Regulatory Affairs (Global Regulatory Lead, Oncology Early Development

AbbVie, United States -
David Meats • Director, Regulatory Services & Medical Affairs Management

Certara, United States -
Munish Mehra, PhD, MS, MSc • Managing Director and Sr. Principal Biostatistician

Quantum Biopharma, United States -
Timothe Menard, PharmD, MSc • Global Head, Quality Excellence Digital | Bioethics Ambassador

F. Hoffmann-La Roche Ltd, Switzerland -
Alexis Reisin Miller, JD • Head, Global Regulatory Policy

Merck & Co., Inc., United States -
Martha Monser • Consumer Safety Officer, Office of Regulatory Operations, CBER

FDA, United States -
Christine Moore, PhD • Executive Director, Global External Advocacy and Standards

Organon & Co., United States -
Erin Mulrooney, MSc, PMP • Director, Portfolio Management

Daiichi Sankyo, Inc, United States -
Sissi Pham, PharmD • Chief Executive Officer

AESARA, United States -
Margaret Richards, PhD, MPH • Open to Work

Pharmacoepidemiology / RWE, United States -
Cynthia Rothblum-Oviatt, PhD • Science Policy Analyst, Rare Disease Team, OND, CDER

FDA, United States -
Leslie Sam • President

Leslie Sam and Associates, LLC, United States -
Earl Seltzer, MBA • Senior Director, Partnerships and Innovation

CTI, United States -
Anjali Shah, PharmD • Executive Director, Business Capabilities and Innovation, WWPS

Bristol-Myers Squibb Company, United States -
Elizabeth Somers, MS • Associate Vice President, Global Project and Alliance Management

Merck Sharp & Dohme LLC, United States -
Mat Soukup, PhD • Deputy Director, Division of Biometrics VII, OB, OTS CDER

FDA, United States -
Shannon Sparklin, MS • Project Manager, OPPD, OMP, CDER

FDA, United States -
Ling Su, PhD • Research Fellow

Yeehong Business School, China -
Linda B Sullivan, MBA • Senior Fellow

Tufts Center For the Study of Drug Development, United States -
Phil Tregunno • Deputy Director - Patient Safety Monitoring

Medicines and Healthcare Products Regulatory Agency (MHRA), United Kingdom -
Pujita Vaidya, MPH • Director, Regulatory Science and Policy

Sanofi, United States -
Paula Walker, MA • Global Head of Risk Based Quality Management

Roche Products Ltd., United Kingdom -
Susan Wang, PhD • Global Head of Biostatistics and Data Sciences Inflammation

Boehringer Ingelheim, United States -
Nancy Watanabe, MS, PMP • Independent Consultant

Independent Consultant, United States -
Keith Wenzel • Volunteer

DIA Study Endpoints Community, United States -
Jennifer Whiteley, PhD, MSc • Executive Director, Head OMNI Evidence for Access

Genentech, A Member of the Roche Group, United States -
Robin Whitsell • President

Whitsell Innovations, Inc., United States -
Judith Zander, MD • Director, Office of Pharmacovigilance and Epidemiology, OSE, CDER

FDA , United States -
Martine Zimmermann, PharmD • Senior Vice President, Head of Global Regulatory Affairs

Ipsen , France
